The class of diagnostic FAP-targeting radiopharmaceuticals labeled with gallium-68 (68Ga-FAPIs) has been shown to achieve a high tumor-to-background ratio (TBR) in various malignancies [5,10]. Here, FAP is linked to neoplasm.